PF-562271
- Generic Name
- PF-562271
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Phase 1
Completed
- Conditions
- Head and Neck NeoplasmProstatic NeoplasmPancreatic Neoplasm
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT00666926
- Locations
- 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath